3:08 PM
 | 
Sep 11, 2018
 |  BC Extra  |  Clinical News

Bavencio, Inlyta combo meets PFS endpoint in first-line RCC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab plus Inlyta axitinib met the primary endpoint of improving progression-free survival vs. Sutent sunitinib in the Phase III JAVELIN Renal 101 trial to treat previously untreated advanced renal cell carcinoma.

According to an interim analysis by an IDMC, Bavencio plus Inlyta significantly improved PFS vs. Sutent in patients with PD-L1-positive tumors, the primary endpoint population, and in the entire patient population regardless of PD-L1 tumor expression, a secondary endpoint. Details were not disclosed.

The partners said the trial will continue as...

Read the full 432 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >